ArticleBMC nephrology2025
Haemodynamically irrelevant pericardial effusion is associated with increased mortality in maintenance hemodialysis patients with end-stage renal disease.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPericardial effusion (PE) is common in patients with end-stage renal disease (ESRD) undergoing maintenance haemodialysis (MHD). The prognostic value of a small, haemodynamically non-compromising PE in patients with ESRD who undergo MHD, is currently lacking.
objectiveThe purpose of this study was to determine the predictive significance of a small, haemodynamically non-compromising PE in MHD patients with ESRD. METHODS AND
resultsPatients with ESRD who received regular dialysis in the Hemodialysis Center of the Fifth Affiliated Hospital of Sun Yat-sen University from January 2017 to December 2020 were retrospectively analyzed. A total of 352 patients with ESRD receiving MHD were enrolled in this study, including 82 patients with PE and 270 patients without PE. The overall median follow-up time was 2.4 years. Compared to the non-PE group, the mortality rate was higher in the PE group (31.7% vs. 18.5%; P = 0.011). PE was associated with an increased all-cause mortality. The Cox proportional hazard model showed that PE was the risk factor for all-cause death (HR: 1.964; 95%CI: 1.020-3.784; P = 0.044), as well as age (HR: 1.049; 95%CI: 1.022-1.076; P = 0.001), diabetes (HR: 2.404; 95%CI: 1.226-4.713; P = 0.011), hemoglobin (HR: 0.983; 95%CI: 0.969-0.997; P = 0.020) and ultrafiltration rate (HR: 1.082; 95%CI: 1.015-1.153; P = 0.015). Echocardiographic follow-up results showed that the mortality rate in the PE persistence group was significantly higher than that in the PE regression group (44.1% vs. 20.7%, P = 0.049).
conclusionIn MHD patients with ESRD, even haemodynamically irrelevant PE is associated with an increased risk of all-cause mortality. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.